Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update
The Open Immunology Journal · 2009
DOI: 10.2174/1874226200902010001 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Open Immunology Journal, 2009. Verfasst von Alejandro Lopez-Requena und 1 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
The use of anti-idiotypic antibodies for cancer treatment continues to be a major field of investigation.One major challenge for tumor immunotherapy is the identification of antigens associated only or preferably with malignant cells.We summarize here some of the most recent preclinical and clinical advances using two targets that can be considered tumor-specific antigens: N-glycolyl (NeuGc)-gangliosides and the idiotype of B cell lymphomas.Recent developments with tumor-associated protein antigens and the role of anti-idiotypic antibodies in autoimmune diseases are also discussed.
Zitieren
APA
Lopez-Requena, A., & Burrone, O. R. (2009). Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update. The Open Immunology Journal. https://doi.org/10.2174/1874226200902010001
Vancouver
Lopez-Requena A, Burrone OR. Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update. The Open Immunology Journal. 2009. doi:10.2174/1874226200902010001
BibTeX
@article{LopezRequena2009,
author = {Lopez-Requena, Alejandro and Burrone, Oscar R.},
title = {Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update},
journal = {The Open Immunology Journal},
year = {2009},
doi = {10.2174/1874226200902010001}
}
EUVIMED